1 study found for:    Phase 2 Study of Zevalin (ibritumomab tiuxetan) versus Zevalin and motexafin gadolinium
Show Display Options
Rank Status Study
1 Terminated Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Zevalin Regimen;   Drug: Moxtezafin Gadolinium

Indicates status has not been verified in more than two years